Key points are not available for this paper at this time.
Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events. (Funded by Novo Nordisk; SOUL ClinicalTrials.gov number, NCT03914326.).
Recent news coverage (OHSU News Feb 2026) and ongoing discussion of incretin therapies in cardiometabolic disease; relevant to multiple ACC.26 themes.
McGuire et al. (Sat,) studied this question.